OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
23. April 2019 08:00 ET
|
OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
31. Juli 2018 16:05 ET
|
OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
01. Juni 2018 16:11 ET
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
12. April 2018 09:00 ET
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
21. August 2017 08:01 ET
|
OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...
Rand Partners With Innovate NY Fund to Invest in Personalized Cancer Medicine Business, Empire Genomics, LLC
01. Juli 2014 17:04 ET
|
Rand Capital Corporation
BUFFALO, NY--(Marketwired - Jul 1, 2014) - Rand Capital Corporation (www.randcapital.com) (NASDAQ: RAND) a Buffalo, New York based Business Development Company (BDC) and Small Business Investment...